Quarterly report [Sections 13 or 15(d)]

Unaudited Condensed Consolidated Statements of Operations

v3.25.3
Unaudited Condensed Consolidated Statements of Operations - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2025
Sep. 30, 2024
Sep. 30, 2025
Sep. 30, 2024
Other revenue $ 0 $ 0 $ 1,404 $ 0
Operating expenses:        
Research and development 177 2,327 780 6,080
General and administrative 547 829 2,955 3,607
Total operating expenses 724 3,156 3,735 9,687
Loss from operations (724) (3,156) (2,331) (9,687)
Other income (expense):        
Interest income 34 51 96 152
Loss on settlement of common stock warrant liabilities 0 0 0 (759)
Change in fair value of warrant liabilities (2) 18 14 157
Total other income (expense) 32 69 110 (450)
Net loss (692) (3,087) (2,221) (10,137)
Net loss attributable to non-controlling interests (9) (11) (21) (29)
Net loss attributable to Avenue (683) (3,076) (2,200) (10,108)
Net loss attributable to common stockholders $ (683) $ (3,076) $ (2,200) $ (18,918)
Net loss per common share attributable to common stockholders, basic and diluted (in dollars per share) $ (0.21) $ (1.92) $ (0.71) $ (17.27)
Weighted average number of common shares outstanding, basic and diluted (in shares) 3,183,558 1,600,189 3,113,464 1,095,180